How Can an International TAVR Consortium Benefit FDA Premarket Evaluation of TAVR Devices: An FDA PreMarket Perspective Bram Zuckerman, MD, FACC - FACC - Document - PDFSEARCH.IO

First Page	Meta Content
	How Can an International TAVR Consortium Benefit FDA Premarket Evaluation of TAVR Devices: An FDA PreMarket Perspective Bram Zuckerman, MD, FACC Add to Reading List Open Document File Size: 343,42 KB Share Result on Facebook Company FACC / / Country United States / / IndustryTerm generation devices / risk devices / / MedicalCondition Major Stroke / II Trials Symptomatic Severe Aortic Stenosis ASSESSMENT / / Organization FDA / Cardiovascular Devices Office / Device Evaluation Center for Devices and Radiological Health / / Person TAO VS / Perspective Bram Zuckerman / Controls Most / / Position General / Major / Director / FDA Division / / Product TAO / / SocialTag Clinical research Research Pharmacology Design of experiments Epidemiology Premarket approval Medical device Humanitarian Device Exemption Center for Devices and Radiological Health Food and Drug Administration

How Can an International TAVR Consortium Benefit FDA Premarket Evaluation of TAVR Devices: An FDA PreMarket Perspective Bram Zuckerman, MD, FACCAdd to Reading List